Last reviewed · How we verify

NCT07176338

Role of Metformin in Posterior Capsule Opacification

Active, enrolled NA Last updated 16 September 2025
What this trial tests

NA trial testing Blood and lens capsule samples for PK testing in Cataract in 40 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
12 October 2022
Primary endpoint
1 October 2025
1 October 2025

Quick facts

Lead sponsorVienna Institute for Research in Ocular Surgery
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposebasic science
Enrollment40
Start date12 October 2022
Primary completion1 October 2025
Estimated completion1 October 2025
Sites1 location across Austria

Drugs / interventions tested

Conditions studied

Sponsor

Vienna Institute for Research in Ocular Surgery

Who can join

Adults 21 to 105, any sex, with Cataract or Diabetes Mellitus Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Determination of concentrations of systemically applied metformin in human lens capsule and its ability to lower the proliferation rate of human lens epithelial cells in vitro.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cataract

Currently open trials in the same condition.

Other Vienna Institute for Research in Ocular Surgery trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07176338.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing